MX2009007546A - Uso de una composicion para la elaboracion de un medicamento y metodo para inhibir la formacion de grasa corporal. - Google Patents

Uso de una composicion para la elaboracion de un medicamento y metodo para inhibir la formacion de grasa corporal.

Info

Publication number
MX2009007546A
MX2009007546A MX2009007546A MX2009007546A MX2009007546A MX 2009007546 A MX2009007546 A MX 2009007546A MX 2009007546 A MX2009007546 A MX 2009007546A MX 2009007546 A MX2009007546 A MX 2009007546A MX 2009007546 A MX2009007546 A MX 2009007546A
Authority
MX
Mexico
Prior art keywords
chromium
composition
iii
manufacture
body fat
Prior art date
Application number
MX2009007546A
Other languages
English (en)
Inventor
Frank Chiahung Mao
Wen-Ying Chen
Chi-Ching Sun
Chia-Hsin Liu
Original Assignee
Maxluck Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxluck Biotechnology Corp filed Critical Maxluck Biotechnology Corp
Publication of MX2009007546A publication Critical patent/MX2009007546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/05—Treating milk before coagulation; Separating whey from curd
    • A23C19/053—Enrichment of milk with whey, whey components, substances recovered from separated whey, isolated or concentrated proteins from milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/05—Treating milk before coagulation; Separating whey from curd
    • A23C19/054—Treating milk before coagulation; Separating whey from curd using additives other than acidifying agents, NaCl, CaCl2, dairy products, proteins, fats, enzymes or microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
    • A23C9/1512—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al uso de una composición para la elaboración de un medicamento y a un método para inhibir la formación de grasa corporal; la composición incluye lactoferrina y un compuesto de cromo trivalente; en éste, el compuesto de cromo está seleccionado del grupo que consta de cloruro de cromo (III) hexahidratado, cloruro de cromo (III), acetato de cromo (III), sulfato de cromo (III), picolinato de cromo, nicotinato de cromo, GFT de cromo, extracto de levadura de cromo, otras sales inorgánicas de cromo trivalente, otras sales orgánicas de cromo trivalente y combinaciones de los mismos; de acuerdo con ello, la composición de la presente invención puede ayudar a transmitir glucosa de las células a los tejidos musculares y reducir así el almacenamiento de grasa convertida de la glucosa, para lograr el propósito de controlar el peso corporal.
MX2009007546A 2008-07-14 2009-07-13 Uso de una composicion para la elaboracion de un medicamento y metodo para inhibir la formacion de grasa corporal. MX2009007546A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW097126609A TWI454221B (en) 2008-07-14 2008-07-14 Composition and method for inhibiting formation of body fat

Publications (1)

Publication Number Publication Date
MX2009007546A true MX2009007546A (es) 2010-03-23

Family

ID=41505375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007546A MX2009007546A (es) 2008-07-14 2009-07-13 Uso de una composicion para la elaboracion de un medicamento y metodo para inhibir la formacion de grasa corporal.

Country Status (8)

Country Link
US (1) US20100009014A1 (es)
JP (1) JP4972673B2 (es)
KR (1) KR101121874B1 (es)
AU (1) AU2009202723B2 (es)
CA (1) CA2670964C (es)
MX (1) MX2009007546A (es)
RU (1) RU2446819C2 (es)
TW (1) TWI454221B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657845B2 (en) * 2014-10-07 2017-05-23 Asm Ip Holding B.V. Variable conductance gas distribution apparatus and method
TWI788561B (zh) * 2019-05-08 2023-01-01 加特福生物科技股份有限公司 促進脂質代謝或幫助體重控制的組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194615A (en) * 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
JPH0623102B2 (ja) * 1985-08-22 1994-03-30 日本臓器製薬株式会社 脂質低下剤
US5480657A (en) * 1993-10-27 1996-01-02 Allen; Ann De Wees T. Composition comprising caffeine chromium and fructose for weight control and use thereof
US5948772A (en) 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
CN1114618C (zh) * 2000-05-19 2003-07-16 程伶辉 三价铬复合物、其乳制品及其制造方法
JP3633852B2 (ja) 2000-06-06 2005-03-30 伶輝 程 三価クロム複合物、その乳製品およびその製造方法
EP1357977B1 (en) * 2000-09-21 2004-07-21 Nutrition 21, Inc. Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia
AU2002359949A1 (en) 2001-12-28 2003-07-24 Nrl Pharma, Inc. Compositions for improving lipid metabolism
WO2003090671A2 (en) * 2002-04-23 2003-11-06 Nutrition 21, Inc. Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
TW200605902A (en) * 2004-08-05 2006-02-16 Maxluck Biotechnology Corp Composition for lowering blood lipid
WO2006063443A2 (en) * 2004-12-14 2006-06-22 Lean Balance Formulations Ltd. Supplement dietary composition for promoting weight loss
TWI276442B (en) * 2005-07-05 2007-03-21 Maxluck Biotechnology Corp Composition of controlling and preventing heart disease
US8895079B2 (en) * 2006-02-09 2014-11-25 National Research Council Of Canada Combinations of botanical extracts for promoting cardiovascular health

Also Published As

Publication number Publication date
AU2009202723A1 (en) 2010-01-28
TW201002212A (en) 2010-01-16
JP2010018615A (ja) 2010-01-28
US20100009014A1 (en) 2010-01-14
TWI454221B (en) 2014-10-01
KR20100007752A (ko) 2010-01-22
AU2009202723B2 (en) 2013-10-31
RU2446819C2 (ru) 2012-04-10
CA2670964A1 (en) 2010-01-14
RU2009125692A (ru) 2011-01-20
CA2670964C (en) 2014-09-30
KR101121874B1 (ko) 2012-03-19
JP4972673B2 (ja) 2012-07-11

Similar Documents

Publication Publication Date Title
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
MY160004A (en) Heterocyclically substituted aryl compounds as hif inhibitors
NZ601489A (en) Cyclic amine compound and acaricide
MX348974B (es) Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
MX341072B (es) Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol.
WO2010080756A3 (en) Harmine derivatives for reducing body weight
WO2012033789A3 (en) Treatment of diseases
MX2009012390A (es) Uso de compuestos de 4-(pirrolidin-1-il)quinolina para exterminar microorganismos clinicamente latentes.
WO2012078757A3 (en) Combination for breast cancer therapy with hsp90 inhibitory compounds
NZ600874A (en) Fluorinated derivatives of deferiprone
WO2009127669A3 (en) Ido inhibitors and therapeutic uses thereof
TN2011000403A1 (en) Compositions and methods for extended therapy wiht aminopyridines
WO2012089828A3 (en) Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2013016452A3 (en) Cancer treatment using bmp inhibitor
WO2012050831A3 (en) Combination treatment for dermatological conditions
MX339302B (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2008070363A3 (en) Intrabodies
AU2011208681A8 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
IL195472A0 (en) Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
MY182983A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2009008656A3 (en) A soap composition for atopic dermatitis containing fermented extract of xanthium strumarium l. and preparation method thereof
TNSN08506A1 (en) Substituted carboxamides
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2009007546A (es) Uso de una composicion para la elaboracion de un medicamento y metodo para inhibir la formacion de grasa corporal.

Legal Events

Date Code Title Description
FG Grant or registration